Sutro Biopharma, Inc. (STRO) — 10-K Filings
All 10-K filings from Sutro Biopharma, Inc.. Browse 3 Annual Report reports with AI-powered summaries and risk analysis.
10-K Filings (3)
-
Sutro Shifts Focus to STRO-004, Eyes Mid-2026 Data Amid Pipeline Re-evaluation
— Mar 23, 2026 Risk: high
Sutro Biopharma, Inc. (STRO) is a clinical-stage oncology company that reported a strategic shift in 2025, deprioritizing luveltamab tazevibulin (STRO-002) deve -
Sutro Biopharma Files 2024 10-K, Details Key Partnerships
— Mar 13, 2025 Risk: medium
Sutro Biopharma, Inc. filed its 2024 10-K on March 13, 2025, reporting on its fiscal year ending December 31, 2024. The company, focused on biological products, -
Sutro Biopharma, Inc. Files 2023 Annual Report on Form 10-K
— Mar 25, 2024 Risk: medium
SUTRO BIOPHARMA, INC. (STRO) filed a Annual Report (10-K) with the SEC on March 25, 2024. Sutro Biopharma, Inc. filed its 2023 Form 10-K on March 25, 2024. The
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX